Top Markets
Coin of the day
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA

FSNUY
Clasificación en acciones #183
Fresenius SE & Co. KGaA, a health care company, provides products and services... Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Precio por acción
$12.65
Capitalización bursátil
$114.00B
Cambio (1 día)
1.36%
Cambio (1 año)
3.52%
País
DE
Comercio Fresenius SE & Co. KGaA (FSNUY)

Categoría

Ratio P/E de Fresenius SE & Co. KGaA (FSNUY)
Ratio P/E al July 2026 TTM: 15.42
Según los últimos informes financieros y el precio de las acciones de Fresenius SE & Co. KGaA, el P/E actual (TTM) de la empresa es 15.42. Al final de 2023, la empresa tenía un P/E de -26.62.
Historial del ratio P/E de Fresenius SE & Co. KGaA desde 2002 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
2026 (TTM) 15.42 -61.55%
2024 40.11 -250.69%
2023 -26.62 -347.86%
2022 10.74 -1.18%
2021 10.87 -12.06%
2020 12.36 -16.72%
2019 14.84 25.16%
2018 11.86 -40.46%
2017 19.91 -21.96%
2016 25.52 -3.60%
2015 26.47 20.88%
2014 21.90 10.82%
2013 19.76 21.32%
2012 16.29 85.50%
2011 8.78 4.03%
2010 8.44 19.22%
2009 7.08 -66.62%
2008 21.21 0.48%
2007 21.10 -10.70%
2006 23.63 253.85%
2005 6.68 10.06%
2004 6.07 -20.73%
2003 7.66 108.28%
2002 3.68 0.00%
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
12.43 -19.39%
US
31.92 107.01%
SA
9.47 -38.57%
US
19.33 25.36%
CN
22.90 48.48%
US
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.